Not yet recruiting
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
NCT07770282
- Conditions
- Antipsychotic-induced Weight Gain, Cardiovascular Risk, Glucose Metabolism Disorders, +9 more
- Locations
-
Not specified